Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $43.93 Average PT from Brokerages

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have been assigned a consensus rating of “Moderate Buy” from the sixteen analysts that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $41.87.

Several equities analysts have commented on the company. Robert W. Baird cut their price objective on Dyne Therapeutics from $46.00 to $32.00 and set an “outperform” rating on the stock in a research report on Wednesday, June 18th. Guggenheim reiterated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a report on Wednesday, June 18th. Chardan Capital reiterated a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, June 17th. Sanford C. Bernstein started coverage on Dyne Therapeutics in a research report on Tuesday. They set a “market perform” rating and a $13.00 target price on the stock. Finally, Piper Sandler decreased their price target on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a report on Friday, February 28th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Rhumbline Advisers increased its holdings in Dyne Therapeutics by 3.0% in the 4th quarter. Rhumbline Advisers now owns 128,244 shares of the company’s stock worth $3,021,000 after acquiring an additional 3,734 shares in the last quarter. Handelsbanken Fonder AB raised its position in Dyne Therapeutics by 16.6% in the fourth quarter. Handelsbanken Fonder AB now owns 22,500 shares of the company’s stock valued at $530,000 after purchasing an additional 3,200 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Dyne Therapeutics by 0.3% in the 4th quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company’s stock worth $5,532,000 after acquiring an additional 698 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Dyne Therapeutics by 2.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 667,452 shares of the company’s stock worth $15,725,000 after purchasing an additional 18,800 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its holdings in Dyne Therapeutics by 100.9% during the 4th quarter. Victory Capital Management Inc. now owns 61,348 shares of the company’s stock valued at $1,445,000 after acquiring an additional 30,811 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Stock Down 2.0%

Dyne Therapeutics stock opened at $10.42 on Monday. The firm’s fifty day moving average is $11.76 and its 200 day moving average is $14.20. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -2.90 and a beta of 1.16. Dyne Therapeutics has a 52-week low of $6.36 and a 52-week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, equities research analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.